Food and Drug Administration: Exempting drugs from bioequivalence requirements to expedite their availability
The Saudi Food and Drug Authority (SFDA) has announced a new draft regulation aimed at updating drug registration standards, specifically exempting certain oral medications from the requirement to undergo clinical bioequivalence studies. This strategic step aims to expedite the evaluation and registration of generic (alternative) drugs and facilitate their accessibility to patients, while maintaining the highest approved standards of efficacy and safety.
General context: What is bioequivalence?
Bioequivalence studies are a cornerstone of the generic drug approval process. These are clinical trials conducted on healthy volunteers to compare the performance of a generic drug with that of the original (reference) drug after administration. The goal is to demonstrate that the generic drug is absorbed by the body and reaches the bloodstream at the same rate and in the same quantity as the original drug, ensuring that it will produce the same therapeutic effect. Despite their importance, these studies are time-consuming and expensive, which can delay the availability of cheaper alternative drugs on the market.
The scientific basis for the decision: Biopharmaceutical Classification System (BCS)
The authority explained that the new regulation is based on the Biopharmaceuticals Classification System (BCS), a globally recognized scientific framework that classifies active pharmaceutical ingredients into four classes based on their water solubility and intestinal permeability. This system provides a reliable alternative to clinical trials, as the in vitro behavior of some drugs can be predicted based on their in vitro properties. Under the draft, the exemption will primarily apply to fast-release solid oral medications belonging to classes 1 and 3 of this system, which are characterized by high solubility, thus making their absorption more predictable.
The importance of the decision and its expected impact
This move is of paramount importance on several levels. Locally, it is expected to encourage domestic pharmaceutical companies to increase their production of generic drugs, thereby enhancing the Kingdom's pharmaceutical security and reducing healthcare costs for citizens and the government, which aligns with the goals of Saudi Vision 2030 to localize vital industries. Regionally, this step positions the Kingdom among the most advanced regulatory nations, reinforcing the Saudi Food and Drug Authority's (SFDA) status as a leading regulatory body in the region. Internationally, this measure reflects compliance with guidelines issued by global organizations such as the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), facilitating the mutual recognition of medicines and supporting the pharmaceutical trade.
Restrictions and controls to ensure patient safety
The agency emphasized that this exemption is not absolute, but rather subject to strict limitations to ensure patient safety. The draft explicitly excludes drugs with a “narrow therapeutic index,” which are sensitive medications where even a slight change in their blood dose could lead to treatment failure or toxicity. Orally or sublingually absorbed drugs are also excluded. The agency stressed the necessity for the inactive ingredients in generic drugs to match those of the reference drug and required companies to provide rigorous scientific justifications and conduct stringent comparative dissolution tests to demonstrate the quality of their products.
